LEADER 03149nam  22006495  450 
001 9910483133403321
005 20251113185014.0
010   $a3-030-68180-7
024 7 $a10.1007/978-3-030-68180-7
035   $a(CKB)4100000011807264
035   $a(MiAaPQ)EBC6525798
035   $a(Au-PeEL)EBL6525798
035   $a(OCoLC)1243305466
035   $a(PPN)254720080
035   $a(DE-He213)978-3-030-68180-7
035   $a(EXLCZ)994100000011807264
100   $a20210323d2021      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aProteinkinase Inhibitors /$fedited by Stefan Laufer
205   $a1st ed. 2021.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021.
215   $a1 online resource (259 pages) $cillustrations
225 1 $aTopics in Medicinal Chemistry,$x1862-247X ;$v36
311 08$a3-030-68179-3 
320   $aIncludes bibliographical references.
327   $aProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors.
330   $aThis book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.
410  0$aTopics in Medicinal Chemistry,$x1862-247X ;$v36
606   $aMedicinal chemistry
606   $aProteins
606   $aBioorganic chemistry
606   $aPharmaceutical chemistry
606   $aMedicinal Chemistry
606   $aProtein Biochemistry
606   $aBioorganic Chemistry
606   $aPharmaceutics
615  0$aMedicinal chemistry.
615  0$aProteins.
615  0$aBioorganic chemistry.
615  0$aPharmaceutical chemistry.
615 14$aMedicinal Chemistry.
615 24$aProtein Biochemistry.
615 24$aBioorganic Chemistry.
615 24$aPharmaceutics.
676   $a572.792
702   $aLaufer$b Stefan
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910483133403321
996   $aProteinkinase inhibitors$91902275
997   $aUNINA